메뉴 건너뛰기




Volumn 8, Issue 5, 2014, Pages 1011-1017

Role of Glucagon-like peptide-1 analogue versus Amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm

Author keywords

artificial pancreas; closed loop; ePID algorithm; exenatide; pramlintide; type 1 diabetes

Indexed keywords

CARBOHYDRATE; EXENDIN 4; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ONDANSETRON; PRAMLINTIDE; AMYLIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; PEPTIDE; VENOM;

EID: 84929780489     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296814542153     Document Type: Article
Times cited : (47)

References (20)
  • 1
    • 77249137912 scopus 로고    scopus 로고
    • Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: Preliminary studies in Padova and Montpellier
    • Bruttomesso D, Farret A, Costa S, et al. Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: preliminary studies in Padova and Montpellier. J Diabetes Sci Technol. 2009;3:1014-1021.
    • (2009) J Diabetes Sci Technol , vol.3 , pp. 1014-1021
    • Bruttomesso, D.1    Farret, A.2    Costa, S.3
  • 2
    • 79953021776 scopus 로고    scopus 로고
    • Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: Summary of the results
    • Kovatchev B, Cobelli C, Renard E, et al. Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results. J Diabetes Sci Technol. 2010;4:1374-1381.
    • (2011) J Diabetes Sci Technol , vol.4 , pp. 1374-1381
    • Kovatchev, B.1    Cobelli, C.2    Renard, E.3
  • 3
    • 84874368884 scopus 로고    scopus 로고
    • Nocturnal glucose control with an artificial pancreas at a diabetes camp
    • Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med. 2013;368:824-833.
    • (2013) N Engl J Med , vol.368 , pp. 824-833
    • Phillip, M.1    Battelino, T.2    Atlas, E.3
  • 4
    • 33645051466 scopus 로고    scopus 로고
    • Continuous glucose monitoring and closed-loop systems
    • Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabetes Med. 2006;23:1-12.
    • (2006) Diabetes Med , vol.23 , pp. 1-12
    • Hovorka, R.1
  • 5
    • 48649083317 scopus 로고    scopus 로고
    • Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas
    • Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care. 2008;31:934-939.
    • (2008) Diabetes Care , vol.31 , pp. 934-939
    • Weinzimer, S.A.1    Steil, G.M.2    Swan, K.L.3    Dziura, J.4    Kurtz, N.5    Tamborlane, W.V.6
  • 6
    • 77249175519 scopus 로고    scopus 로고
    • Overnight closedloop insulin delivery with model predictive control: Assessment of hypoglycemia and hyperglycemia risk using simulation studies
    • Wilinska ME, Budiman ES, Taub MB, et al. Overnight closedloop insulin delivery with model predictive control: Assessment of hypoglycemia and hyperglycemia risk using simulation studies. J Diabetes Sci Technol. 2009;3:1109-1120.
    • (2009) J Diabetes Sci Technol , vol.3 , pp. 1109-1120
    • Wilinska, M.E.1    Budiman, E.S.2    Taub, M.B.3
  • 7
    • 15944409169 scopus 로고    scopus 로고
    • The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes
    • Heptulla RA, Rodriguez LM, Bomgaars L, Haymond MW. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. Diabetes. 2005;54:1100-1107.
    • (2005) Diabetes , vol.54 , pp. 1100-1107
    • Heptulla, R.A.1    Rodriguez, L.M.2    Bomgaars, L.3    Haymond, M.W.4
  • 8
    • 69249228579 scopus 로고    scopus 로고
    • Pramlintide lowered glucose excursions and was well-Tolerated in adolescents with type 1 diabetes: Results from a randomized, single-blind, placebo-controlled, crossover study
    • Chase HP, Lutz K, Pencek R, Zhang B, Porter L. Pramlintide lowered glucose excursions and was well-Tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. J Pediatr. 2009;155:369-373.
    • (2009) J Pediatr , vol.155 , pp. 369-373
    • Chase, H.P.1    Lutz, K.2    Pencek, R.3    Zhang, B.4    Porter, L.5
  • 9
    • 77956074558 scopus 로고    scopus 로고
    • The role of adjunctive exenatide therapy in pediatric type 1 diabetes
    • Raman VS, Mason KJ, Rodriguez LM, et al. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care. 2010;33:1294-1296.
    • (2011) Diabetes Care , vol.33 , pp. 1294-1296
    • Raman, V.S.1    Mason, K.J.2    Rodriguez, L.M.3
  • 10
    • 84869090428 scopus 로고    scopus 로고
    • Effect of insulin feedback on closed-loop glucose control: A crossover study
    • Ruiz JL, Sherr JL, Cengiz E, et al. Effect of insulin feedback on closed-loop glucose control: A crossover study. J Diabetes Sci Technol. 2012;6:1123-1130.
    • (2012) J Diabetes Sci Technol , vol.6 , pp. 1123-1130
    • Ruiz, J.L.1    Sherr, J.L.2    Cengiz, E.3
  • 11
    • 66149084084 scopus 로고    scopus 로고
    • Twenty-four-hour simultaneous subcutaneous Basal-bolus administration of insulin and amylin in adolescents with type 1 diabetes decreases postprandial hyperglycemia
    • Heptulla RA, Rodriguez LM, Mason KJ, Haymond MW. Twenty-four-hour simultaneous subcutaneous Basal-bolus administration of insulin and amylin in adolescents with type 1 diabetes decreases postprandial hyperglycemia. J Clin Endocrinol Metab. 2009;94:1608-1611.
    • (2009) J Clin Endocrinol Metab , vol.94 , pp. 1608-1611
    • Heptulla, R.A.1    Rodriguez, L.M.2    Mason, K.J.3    Haymond, M.W.4
  • 12
    • 0032976939 scopus 로고    scopus 로고
    • Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients
    • Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999;22:1137-1143.
    • (1999) Diabetes Care , vol.22 , pp. 1137-1143
    • Toft-Nielsen, M.B.1    Madsbad, S.2    Holst, J.J.3
  • 13
    • 79959415768 scopus 로고    scopus 로고
    • Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual beta-cell function
    • Kielgast U, Holst JJ, Madsbad S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual beta-cell function. Diabetes. 2011;60:1599-1607.
    • (2011) Diabetes , vol.60 , pp. 1599-1607
    • Kielgast, U.1    Holst, J.J.2    Madsbad, S.3
  • 14
    • 84866727216 scopus 로고    scopus 로고
    • Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes
    • Weinzimer SA, Sherr JL, Cengiz E, et al. Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes. Diabetes Care. 2012;35:1994-1999.
    • (2012) Diabetes Care , vol.35 , pp. 1994-1999
    • Weinzimer, S.A.1    Sherr, J.L.2    Cengiz, E.3
  • 15
    • 78449294264 scopus 로고    scopus 로고
    • Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus
    • Lee NJ, Norris SL, Thakurta S. Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus. Ann Fam Med. 2010;8:542-549.
    • (2011) Ann Fam Med , vol.8 , pp. 542-549
    • Lee, N.J.1    Norris, S.L.2    Thakurta, S.3
  • 16
    • 77953199798 scopus 로고    scopus 로고
    • Safety of pramlintide added to mealtime insulin in patients with type 1 or type 2 diabetes: A large observational study
    • Pencek R, Roddy T, Peters Y, et al. Safety of pramlintide added to mealtime insulin in patients with type 1 or type 2 diabetes: A large observational study. Diabetes Obes Metab. 2010;12: 548-551.
    • (2011) Diabetes Obes Metab , vol.12 , pp. 548-551
    • Pencek, R.1    Roddy, T.2    Peters, Y.3
  • 17
    • 84869492009 scopus 로고    scopus 로고
    • Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: Clinical studies and practical approaches to therapy
    • Tobin GS, Cavaghan MK, Hoogwerf BJ, McGill JB. Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy. Int J Clin Pract. 2012;66:1147-1157.
    • (2012) Int J Clin Pract , vol.66 , pp. 1147-1157
    • Tobin, G.S.1    Cavaghan, M.K.2    Hoogwerf, B.J.3    McGill, J.B.4
  • 18
    • 79959392262 scopus 로고    scopus 로고
    • Liraglutide as additional treatment for type 1 diabetes
    • Varanasi A, Bellini N, Rawal D, et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol. 2011;165: 77-84.
    • (2011) Eur J Endocrinol , vol.165 , pp. 77-84
    • Varanasi, A.1    Bellini, N.2    Rawal, D.3
  • 19
    • 79551569614 scopus 로고    scopus 로고
    • Leptin treatment confers clinical benefit at multiple stages of virally induced type 1 diabetes in BB rats
    • Kruger AJ, Yang C, Lipson KL, et al. Leptin treatment confers clinical benefit at multiple stages of virally induced type 1 diabetes in BB rats. Autoimmunity. 2011;44:137-148.
    • (2011) Autoimmunity , vol.44 , pp. 137-148
    • Kruger, A.J.1    Yang, C.2    Lipson, K.L.3
  • 20
    • 50049108982 scopus 로고    scopus 로고
    • The accuracy and efficacy of real-Time continuous glucose monitoring sensor in patients with type 1 diabetes
    • Mastrototaro J, Shin J, Marcus A, Sulur G, Investigators SCT. The accuracy and efficacy of real-Time continuous glucose monitoring sensor in patients with type 1 diabetes. Diabetes Technol Ther. 2008;10:385-390.
    • (2008) Diabetes Technol Ther , vol.10 , pp. 385-390
    • Mastrototaro, J.1    Shin, J.2    Marcus, A.3    Sulur, G.4    Sct, I.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.